Colin Ross BSc, MSc, PhD
Professor (Tenure) and Associate Dean, Research
Scientist, BC Children’s Hospital Research Institute
Scientist, Centre for Advancing Health Outcomes, St. Paul’s Hospital
Dr. Ross’s research seeks to develop new medicines and optimize the safe and effective use of medicines to better treat disease. Dr. Ross’s research is focused on treating pediatric cancer and genetic diseases by incorporate genetics and genomics into guiding, optimizing, and developing new medicines to better treat these devastating conditions.
Dr. Ross has published over 220 scientific articles in top scientific and medical journals, including Nature Genetics, New England Journal of Medicine, JAMA, Circulation, Cell Stem Cell, CRISPR Journal, and Molecular Therapy. His h-index is 58 and his work has been cited more than 12,500 times. Dr. Ross has been invited to present at over 200 local, national, and international conferences, seminars, and public lectures.
Improving the safety of medicines: Together with collaborators across Canada and the USA, Dr. Ross helped establish the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), a Canada-wide network of clinicians and researchers to create a biobank and clinical data repository of patients who have suffered severe adverse drug reactions (ADRs) (Ross et al., 2007, 2009, 2010, 2011). Dr. Ross and colleagues have identified genetic risk factors for a growing number of serious ADRs, such as cisplatin-induced deafness (Ross et al., Nat Gen, 2009; Pussegoda et al., Clin Pharm Ther, 2013; Drogemoller et al, JAMA Oncol, 2017), codeine-related deaths (Madadi et al., 2009, Kelly et al., 2012; Sistonen et al., 2012), and doxorubicin-induced heart toxicity. In a Canada-wide program, Dr. Ross provides rapid-turnaround pharmacogenetic testing to determine individual susceptibility to ADRs for several chemotherapies for pediatric oncology patients at 10 pediatric oncology centres across Canada.
Gene therapy: Dr. Ross developed Glybera, the first gene therapy to receive formal regulatory approval (EMA, 2012). This is an AAV-based gene therapy for the treatment of a rare disease called LPL Deficiency (Ross et al., 2004, 2005, 2006, 2006). Clinical trials demonstrated the safety and effectiveness of the approach (Stroes et al., 2008; Gaudet et al., 2012, 2016) and in 2012 it became the first gene therapy to receive formal regulatory approval (“First gene therapy approved”, Nat Biotech, 2012). Dr. Ross’s research now aims to improve the cost-effectiveness of future gene therapies and improve the in vivo delivery of gene therapies to specific tissues.
Therapeutic genome editing: Previously, my research helped show how NextGen genome sequencing can be implemented to rapidly diagnose patients with rare genetic diseases and improve their disease management (e.g., Tarailo-Graovac et al, NEJM, 2016; van Kuilenburg et al, NEJM, 2019). Building upon the previous research in gene therapy, Dr. Ross is developing novel therapeutics that use genome editing to treat genetic diseases. We developed the LumA mouse to facilitate this research (Yu et al, Mol Ther, 2023). Dr. Ross is the external scientific advisor for the NIH’s “TARGETED Challenge” Genome Editor Delivery program (2022-2028) launched in May 2023 ($6.6M over 5 years) to address the challenges of gene editor delivery to targeted peripheral tissues and the brain.
Gibson, KM, Drögemöller, BI, Foell, D, Benseler, SM, Graham, J, Hancock, REW, Luqmani, RA, Cabral, DA, Brown, KL, Ross, CJ. HLA-DPB1 is associated with ANCA-associated vasculitis in children. Arthritis & Rheumatology. 75(6), 1048-1057, June, 2023. doi: 10.1002/art.42423. PMID: 36530128. (SA) (IF 15.48) Ranked 3 of 61 journals in rheumatology.
Yu, SY, Carlaw, T, Thomson, T, Birkenshaw, A, Basha, G, Kurek, D, Huang, C, Kulkarni, J, Zhang, LH, Ross, CJ. A luciferase reporter mouse model to optimize in vivo gene editing validated by lipid nanoparticle delivery of adenine base editors. Molecular Therapy. 2023 Apr 5;31(4):1159–1166. PMID: 36793209 (SA) (IF 12.91) Ranked 3 of 153 journals in drug discovery. (Awarded the 2024 Faculty of Pharmaceutical Sciences Mitchell-Dwivedi Graduate Award for the top publication by a graduate student in 2023.)
Hasbullah, JS, Scott, EN, Bhavsar, AP, Gunaretnam, EP, Miao, FM, Soliman, H, Carleton, BC, Ross, CJ. All-trans retinoic acid (ATRA) regulates key genes in the RARG-TOP2B pathway and reduces anthracycline-induced cardiotoxicity. PLoS ONE 17(11), Nov. 4, 2022. PMID: 36331922 (SA) (IF 6.5). Ranked 12 of 225 journals in Biochemistry, Genetics, & Molecular Biology. This paper describes the final results of my CIHR project grant to identify genetic predictors of life-threatening anthracycline (chemotherapy)-induced heart failure and build upon these findings to explore a novel cardio-protective intervention using ATRA (vitamin A derivative) to prevent the toxicity. ATRA proved to be a highly effective strategy to reduce toxicity in our preclinical (mouse) study.
Kazemian, P., Yu, S-Y., Thomson, T, Birkenshaw, A., Blair, L., Ross, CJ. Lipid Nanoparticle-Based Delivery of CRISPR/Cas9 Genome Editing Components. Molecular Pharmaceutics. 2022 Jun 6;19(6):1669-1686. PMID: 35594500 (SA) (IF 4.94). Ranked 14 of 183 journals in pharmaceutical sciences. This paper outlines an emerging research focus of my lab that is building upon $1.5M in new funding (2022-2024) from the Nanomedicine Innovation Network (supported by NCE: National Centres of Excellence) to develop new, effective and safe therapeutics for in vivo therapeutic genome editing to treat genetic diseases.
Yu, S.A., Birkenshaw, A., Thomson, T., Carlaw, T., Zhang, L, Ross, CJ. Increasing the Targeting Scope of CRISPR Base Editing System Beyond NGG. CRISPR Journal. 2022 Apr;5(2):187–202. (SA) (IF 6.1). PMID: 35238621.
Magdy, T., Jouni, M., Kuo, H.-H., Weddle, C.J., Lyra-Leite, D., Fonoudi, H., Romero-Tejeda, M., Gharib, M., Javed, H., Fajardo, G., Ross, CJ. Carleton, B.C., Bernstein, D., and Burridge, P.W. Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity. Circulation. 2022 Jan 25;145(4):279–294. Epub 2021 Dec 7. PMID: 34874743 (SA) (Impact factor 29.69). Ranked 2 of 349 journals in cardiology and cardiovascular medicine. This paper describes functional studies that validate the role of the SLC28A3 gene (which my team identified in 2012 and replicated in 2013) as a genetic risk factor of anthracycline-induced heart failure in pediatric cancer patients who receive doxorubicin chemotherapy.
Magdy T, Jiang Z, Jouni M, Fonoudi H, Lyra-Leite D, Jung G, Romero-Tejeda M, Kuo HH, Fetterman KA, Gharib M, Burmeister BT, Zhao M, Sapkota Y, Carleton BC, Ross CJD, Bernstein D, Burridge PW. RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. Cell Stem Cell. 2021 Sep 14:S1934–5909(21)00343-X. PMID: 34525346. (SA) (IF 24.63; citations 7). Ranked 3 of 173 journals in molecular medicine.
Scott, E., Wright, GEB, Drogemoller, B., Hasbullah, J.S., Gunaretnam, EP, Miao, F., Bhavsar, AP, Shen, F, Schneider, BP, Carleton, BC, Ross, CJD. Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicity. NaturePG Genomic Medicine. 2021 May 21;6(1):35. doi: 10.1038/s41525-021-00199-4. PMID: 34021165 (SA) (IF 8.62). Ranked 10 of 96 journals in clinical genetics.
Li, Y, Ross, R., Ross, CJ. A Novel Approach to Bio-Friendly Microplastic Extraction with Ascidians. Journal of Student Research. 10(4) 1–8. 2021.
Scott EN, Hasbullah JS, Carleton BC, Ross CJ. Prevention of adverse drug effects: a pharmacogenomic approach. Curr Opin Pediatr. 2020 Oct;32(5):646–653. PMID: 32796162. (SA) (IF 2.85) Ranked 71 of 310 journals in pediatrics.
Carlaw, TM., Zhang, LH, Ross, CJD. CRISPR/Cas9 Editing Safety in Light of the Need for New Therapeutics. Hum Gene Ther. 2020 Aug;31(15-16):794–807. doi: 10.1089/hum.2020.111. PMID: 32586150. (SA) (IF 5.69). Ranked 29 of 169 journals in molecular medicine.
Gibson KM, Morishita KA, Dancey P, Moorehead P, Drögemöller B, Han X, Graham J, Hancock REW, Foell D, Benseler S, Luqmani R, Yeung RSM, Shenoi S, Bohm M, Rosenberg AM, Ross CJD, Cabral DA, Brown KL. Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis. Arthritis Rheumatol. 2019. Oct;71(10):1747–1755. PMID: 31008556. (SA) (IF 9.002; citations 24), Ranked 3 of 60 journals in rheumatology).
Matthews AM, Blydt-Hansen I, Al-Jabri B, Andersen J, Tarailo-Graovac M, Price M, Selby K, Demos M, Connolly M., Drogemoller, B., Shyr, C., Mwenifumbo J, Elliot AM, Lee J, Ghani A, Stockler S, Salvarinova R, Vallance H., Sinclair, G., CAUSES Study, Ross, CJ, Wasserman, W., McKinnon, ML, Horvath G, Goez, H., van Karnebeek, C.D. Atypical Cerebral Palsy: Genomics Analysis Enables Precision Medicine. Genet Med. 2019 Jul;21(7):1621–1628. PMID: 30542205 (CA) (IF 9.94; citations 32), Ranked 6 of 100 journals in clinical medicine.
Wright G, Collins J, Kay C, McDonald C, Dolzhenko E, Xia Q, Bečanović K, Drögemöller B, Semaka A, Nguyen C, Trost B, Richards F, Bijlsma E, Squitieri F, Ross CJ, Scherer S, Eberle M, Yuen R, Hayden M. Length of uninterrupted CAG repeats, independent of polyglutamine size, result in increased somatic instability and hastened age of onset in Huntington disease. Am J Hum Genet. 2019 Jun 6;104(6):1116–1126. PMID: 31104771 (CA) (IF 9.924; citations 82). Ranked 3 of 100 journals in clinical genetics.
van Kuilenburg, et al., Glutaminase Deficiency Caused by Short Tandem Repeat Expansion in GLS. New England Journal of Medicine. April 11, 2019. 380:1433-1441 (CA) (IF 176.08; citations 44; Ranked 3 of 2836 journals in medicine).
Wright, GEB, Amstutz, U, Drögemöller, B.I., Shih, J., Rassekh, S.R., Carleton, BC, and Ross, CJ. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clinical Pharmacology & Therapeutics. Feb 105(2):402-410. 2019. PMID: 29999516. (SA) (IF 7.2; citations 43; Ranked 16 of 261 journals in pharmacology, medical).
Kowalec, K#, Wright, G#, (# co-first author) Drögemöller, BI, Aminkeng, F, Bhavsar, AP, Kingwell, E, Yoshida, EM, Traboulsee, A, Marrie, RA, Kremenchutzky, M, Campbell, TL, Duquette, P, Chalasani, N, Wadelius, M, Hallberg, P, Xia, Z, De Jager, PL, Denny, JC, Davis, MF, Ross, CJ*, Tremlett, H, Carleton, BC* (*co-senior authors). A novel pharmacogenomic risk locus for interferon-beta-induced liver injury in multiple sclerosis. Nature Genetics. 50, 1081–1085 2018, PMID: 30013178. (SA) (IF 41.30, citations 30). Ranked 1 of 339 primary literature journals in genetics.
Drögemöller, B.I., Brooks, B., Critchley, C., Monzon, JG, Wright, GEB, Liu, G, Renouf, DJ, Kollmannsberger, CK, Bedard, PL, Hayden, MR, Gelmon, K, Carleton, BC, & Ross, CJ. Further investigation of the role of ACYP2 and WFS1 pharmacogenomic variants in the development of cisplatin-induced ototoxicity in testicular cancer patients. Clinical Cancer Research. 2018 Apr 15;24(8):1866–1871. PMID: 29358504. (SA) (IF 9.6; citations 33). Ranked 9 of 221 journals in cancer research.
Wright, G.E.B., Carleton, B., Hayden, M., Ross, C.J. The global spectrum of protein-coding pharmacogenomic diversity. Pharmacogenomics Journal. 2018 Jan;18(1):187–195. PMID: 27779249 (SA) (IF 3.81; Citations 59). Ranked 101 of 784 journals in pharmacology, pharmaceutics, and toxicology.
Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJ*, Gelmon KA*, Carleton BC*. (*Co-senior author). Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients with Testicular Cancer. JAMA Oncology. 2017; 3(11):1558-1562. PMID: 28448657. (SA) (IF 20.9; citations 40). Ranked 30 of 2,863 journals in medicine (misc).
Bhavsar AP, Gunaretnam EP, Li Y, Hasbullah J, Carleton BC, Ross CJ. Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines. PLoS One. 2017 Apr 13;12(4):e0175711. PubMed PMID: 28406961. (SA) (IF 6.5; Citations 20). Ranked 12 of 225 journals in Biochemistry, Genetics, & Molecular Biology.
Tarailo-Graovac, M., Shyr, C., Ross, CJ, Horvath, G.A., Salvarinova, R., Ye, X., Zhang, L.H., Bhavsar, A.P., Drögemöller, B., Abdelsayed, M., Alfadhel, M., Armstrong, L., Baumgartner, M.R., Burda, P., Connolly, M.B., Cameron, J., Demos, M., Dewan, T., Dionne, J., Evans, M., Friedman, J.M., Garber, I., Lewis, S., Ling, J., Mandal, R., Mattman, A., McKinnon, M., Michoulas, A., Metzger, D., Ogunbayo, O.A., Rakic, B., Rozmus, J., Ruben, P., Sayson, B., Santra, S., Schultz, K.R., Selby, K., Shekel, P., Sirrs, S., Skrypnyk, C., Superti-Furga, A., Turvey, S.E., Van Allen, M.I., Wishart, D., Wu, J., Wu, J., Zafeiriou, D., Kluijtmans, L., Wevers, R.A., Eydoux, P., Lehman, A.M., Vallance, H., Stockler-Ipsiroglu, S, Sinclair, G., Wasserman, W.W., van Karnebeek, C.D. Exome sequencing and the management of neuro-metabolic disorders. New England Journal of Medicine; 374: 2246–2255. June 9, 2016. (CA) (IF 176.08; Citations 257). Ranked 3 of 2836 journals in medicine (misc).
Aminkeng, F, Bhavsar, A, Rassekh, SR, Brunham, L, Weissman, C, Lee, J, Visscher, H, Rieder, MJ, Bernstein, D, Carleton, BC, MR Hayden, Ross, CJ. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nature Genetics. 2015 Sep; 47(9):1079–84. (SA) (IF 41.30; Citations 192). Ranked 1 of 339 primary literature journals in genetics.
Visscher, H., Rassekh, SR, Sandor, G, Caron, HN, van Dalen, EC, Kremer, LC, van der Pal, J, Brown, AMK, Phillips, M, Rogers, PC, Rieder, MJ, Carleton, BC, Hayden, MR, Ross, CJ. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. J Pharmacogenomics. 2015;16(10):1065–76. (SA) (IF 3.81; Citations 82). Ranked 101 of 784 journals in pharmacology, pharmaceutics, and toxicology.
Tarailo-Graovac M, Sinclair G, Stockler-Ipsiroglu S, Van Allen M, Rozmus J, Shyr C, Biancheri R, Oh T, Sayson B, Lafek M, Ross CJ, Robinson WP, Wasserman WW, Rossi A, van Karnebeek CD. The genotypic and phenotypic spectrum of PIGA deficiency. Orphanet J Rare Dis. 2015. 27;10(1):23. PMID: 25885527. (CA) (IF 3.61; Citations 67). Ranked 34 of 100 journals in clinical genetics.
Smolina, K., Weymann, D., Morgan, S., Ross, CJ, Carleton, BC. Association between regulatory advisories and codeine prescribing to postpartum women. JAMA. 2015 May 12;313(18):1861–2. (CA) (IF 47.6). Ranked 15 of 2863 journals in medicine.
Jiménez-Triana CA, Castelán-Martínez OD, Rivas-Ruiz R, Jiménez-Méndez R, Medina A, Clark P, Rassekh R, Castañeda-Hernández G, Carleton B, Medeiros M; Canadian Pharmacogenomics Network for Drug Safety Consortium (Ross, CJ). Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study. Medicine (Baltimore). 2015 Aug; 94(34): 1–7. PMID: 26313789 (CA) (IF 2.03; citations 24). Ranked 819 of 2863 journals in medicine (misc).
Wang, C, Xu, M, Lo, R, Procyshyn, R, Vila-Rodriguez, F, White, R, Ross, CJ, Honer, W, Barr, A Development of a cost-efficient novel method for rapid, concurrent genotyping of 5 common single nucleotide polymorphisms of the Brain Derived Neurotrophic Factor (BDNF) gene by Tetra-Primer Amplification Refractory System. International Journal of Methods in Psychiatric Research. 2015 Sep;24(3):235–44. PMID: 26118823. (CA) (IF 2.5). Ranked 101 of 525 journals in psychiatry and mental health.
Kelly, LE, Chaudhry, S.A., Rieder, MJ Jong, G, Moretti, ME, Lausman, A, Ross, CJ, Berger, H, Carleton, BC, Hayden, MR, Madadi, P, Koren, G. A Clinical Tool for Reducing Central Nervous System Depression among Neonates Exposed to Codeine through Breast Milk. PLOS One (2013) Jul 29;8(7):e70073. (CA) PMID: 23922910 (IF 6.5; Citations 35). Ranked 12 of 225 journals in biochemistry, genetics, & molecular biology.
Madadi P, Sistonen J, Silverman G, Gladdy R, Ross CJ, Carleton BC, Carvalho JC, Hayden MR, Koren G. Life-threatening adverse events following therapeutic opioid administration in adults: Is pharmacogenetic analysis useful? Pain Res Manag. 2013 May-Jun;18(3):133–6. PMID: 23748253 (CA) (IF 2.02; Citations 26). Ranked 41 of 124 journals in anesthesiology and pain medicine.
Lam J, Kelly L, Matok I, Ross CJ, Carleton BC, Hayden MR, Madadi P, Koren G. Putative Association of ABCB1 2677G>T/A With Oxycodone-Induced Central Nervous System Depression in Breastfeeding Mothers. Ther Drug Monit. 2013 Aug; 35(4):466–72. PMID: 23783165 (CA) (IF 3.68; Citations 19). Ranked 118 of 254 journals in pharmacology (medical).
Pussegoda, K., Ross, CJ, Visscher, H., Yazdanpanah, M., Brooks, B., Rassekh, SR, Carleton, BC, Hayden, MR & the CPNDS Consortium. Replication of TPMT genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol & Therapeutics. 2013 Aug; 94(2):243-51. PMID: 23588304 (FA*) (IF 7.2; Citations 120). Ranked 16 of 261 journals in pharmacology (medical).
Visscher, H, Ross, CJ, Rassekh, SR, Sandor, G, Caron, HN, van Dalen, EC, Kremer, LC, van der Pal, J, Rogers, PC, Rieder, MJ, Carleton, BC, Hayden, MR, & the CPNDS consortium. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatric Blood & Cancer. 2013 Aug;60(8):1375-81. PMID: 23441093 (FA*) (IF 2.65; Citations 144). Ranked 29 of 301 journals in child health.
Amstutz U, Ross CJ, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC; CPNDS Consortium. HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children. Clin Pharmacol Ther. 2013 Jul;94(1):142–9. PMID: 23588310 (FA*) (IF 7.2; Citations 111). Ranked 16 of 261 journals in pharmacology (medical).
Kastelein, J, Ross, CJ, & Hayden, MR. From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world. [REVIEW] Hum Gene Ther. 2013 May;24(5):472–8. PMID: 23578007 (FA) (IF 4.71; Citations 56). Ranked 29 of 169 journals in molecular medicine.
Shaw, K., Amstutz, U., Jimenez-Mendez, R., Ross, CJ., Carleton, B.C. Suspected Opioid Overdose Case Resolved by CYP2D6 Genotyping. Therapeutic Drug Monitoring. 2012 Apr;34(2):121–3. PMID: 22406651 (CA) (IF 3.18; citations 10). Ranked 119 of 260 journals in pharmacology (medical).
Kelly, LE, Rieder, M, van den Anker, J, Malkin, B, Ross, CJ, Neely, M, Carleton, B, Hayden, M, Madadi, P, Koren, G. More Codeine Fatalities After Tonsillectomy in North American Children. Pediatrics. 2012 May;129(5):e1343–7. PMID: 22492761 (CA) (IF 7.12; Citations 405). Ranked 2 of 301 journals in pediatrics.
Sistonen, J, Madadi, P, Ross, CJ, Yazdanpanah, M, Landsmeer, M, Nauta, M, Carleton, BC, Koren, G, Hayden, MR. Prediction of codeine toxicity in neonates and their mothers using a novel combination of genetic markers. Clinical Pharmacology & Therapeutics. 2012 Apr;91(4):692-9. PMID: 22398969 (FA*) (IF 7.2; Citations 67). Ranked 16 of 261 journals in pharmacology (medical).
Visscher, H, Ross, CJ, Rassekh, R, Barhdadi, A, Dubé, MP, al-Saloos, H, Sandor, GS, Caron, HN, van Dalen, EC, Kremer, LC, van der Pal, HJ, Brown, AMK, Rogers, PC, Phillips, MS, Rieder, M, Carleton, BC, Hayden, MR, & the CPNDS consortium. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. Journal of Clinical Oncology. 30:1422–1428, 2012. PMID: 21900104 (FA*) (IF 44.54; Citations 362). Ranked 2 of 220 primary literature journals in cancer research.
Ross, CJ, Visscher, H., Rassekh, S.R., Castro-Pastrana, L., Shereck, E., Carleton, B.C., and Hayden, M.R. Pharmacogenomics of serious adverse drug reactions in pediatric oncology {Review} Journal of Population Therapeutics and Clinical Pharmacology. 2011;18:e134–51. PMID: 21467604 (FA) (IF 3.81; Citations 45). Ranked 164 of 260 journals in medical pharmacology.
Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC and Hayden MR and the CPNDS Consortium. The Canadian Pharmacogenomics Network for Drug Safety - A Model for Safety Pharmacology. Thyroid. 2010 Jul;20(7):681–7. PMID: 20578893 (FA) (IF 7.56; Citations 63). Ranked 6 of 135 journals in endocrinology.
Madadi, P, Hildebrandt, D, Gong, I, Schwarz, U, Ciszkowski, C, Ross, C.J., Sistonen, J, Carleton, B, Hayden, MR, Lauwers, A, Koren, G. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics. Oct;126(4):e986–9. 2010. PMID: 20837591 (CA) (IF 5.71; Citations 92). Ranked 2 of 301 journals in pediatrics.
Madadi, P, Ross, CJ, Hayden, MR, Carleton, BC, Gaedigk, A, Leeder, JS, Koren, G. Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Case–Control Study. Clinical Pharmacology & Therapeutics. 2009 Jan;85(1):31-5. PMID: 18719619. (FA*) (IF 7.2; Citations 342). Ranked 16 of 261 journals in pharmacology).
Visscher, H, Ross, CJ, Dubé, MP, Carleton, B, Hayden, MR. Application of principal component analysis to pharmacogenomic studies in Canada. J Pharmacogenomics. 2009 Dec;9(6):362–72. PMID: 19652663. (FA*) (IF 2.53; Citations 29). Ranked 101 of 784 journals in pharmacology, pharmaceutics, and toxicology.
Ross, CJ, Katzov-Eckert, H, Dubé, MP, Brook, B, Rassekh, SR, Barhdadi, A, Feroz-Zadac, Y, Visscher, H, Brown, AMK, Rogers, PC, Phillips, MS, Carleton, B, Hayden, MR. Genetic variations in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genetics. 41 (12), 1345–1349 Dec. 2009. (FA) (IF 41.30; Citations 327). Ranked 1 of 339 primary literature journals in genetics.
Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, Maas MM, Zwinderman AH, Ross CJ, Aronica E, High KA, Levi MM, Hayden MR, Kastelein JJ, Kuivenhoven JA. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2303–4. PMID: 18802015. (CA) (IF 6.6; Citations 196). Ranked 17 of 362 journals in cardiology and vascular medicine.
Ross, CJ, Katzov, H, Carleton, B, Hayden, MR. Pharmacogenomics and its Implications for Autoimmune Disease. [REVIEW] Journal of Autoimmunity. Mar-May; 28(2-3):122–8. 2007. PMID: 17418528. (FA) (IF 7.61; Citations 26). Ranked 32 of 190 journals in immunology and allergy.
Ross, CJ, Carleton, B. Warn, DG, Stenton, SB, Rassekh, SR, Hayden, MR. Genotypic Approaches to Therapy in Children (GATC): A National Active Surveillance Network to Study the Pharmacogenomics of Severe Adverse Drug Reactions in Children. Annals of the New York Academy of Sciences. 1110:177–92. 2007. PMID: 17911433. (FA) (IF 4.7; Citations 33). Ranked 31 of 243 journals in biochemistry, genetics and molecular biology (miscellaneous).
Ross, CJ, Twisk, J., Kuivenhoven, J.A., Rip, J., Kastelein, J.J., and Hayden, M.R. Gene Therapy with Lipoprotein Lipase Variant S447X. Arterioscler. Thromb. Vasc. Biol. 26: 25-28. 2006. PMID: 16484602. (FA) (IF 6.6; citations 7). Ranked 17 of 362 journals in cardiology and vascular medicine.
Ross, CJ, Twist, J., Kuivenhoven, J.A., Rip, J., Kastelein, J.J.P., Hayden, M.R. ROSS, CJ, Gene therapy with lipoprotein lipase variant S447X. Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):e25; author reply e25–8. doi: 10.1161/01.ATV.0000203502.01793.8d. PubMed PMID: 16484602.
Ross, CJ, Twisk, J. Meulenberg, J.J.M., Kuivenhoven, J.A., Miao, F., Scheenhart-van der Meer, J.W.C, Moraal, E., Oranje, P.P.A., Hermens, W.T..J.M.C., Kastelein, J.J.P., Hayden, M.R. Correction of Feline Lipoprotein Lipase Deficiency with AAV1-mediated gene transfer of the naturally-occurring LPLS447X beneficial mutation. Hum. Gen. Ther. 2006. 17(5):487–99. PMID: 16716106. (FA) (IF 4.71; Citations 89). Ranked 29 of 169 journals in molecular medicine.
Ross CJ, Liu, G., Kuivenhoven, J.A., Twisk, J., Rip, J., van Dop, W., Ashbourne Excoffon, K.J., Lewis, S.M., Kastelein, J.J., Hayden, M.R. Complete Rescue of Lipoprotein Lipase-Deficient Mice by Somatic Gene Transfer of the Naturally Occurring LPLS447X Beneficial Mutation. Arterioscler. Thromb. Vasc. Biol. 25(10):2143–50. October 2005. PMID: 16002740. (FA) (IF 6.6; Citations 75). Ranked 17 of 362 journals in cardiology and vascular medicine.
Ross, CJ, Twist, J., Meulenberg, J.J.M., Liu, G., Van Den Oever, K. Moraal, E., Hermens, W.T., Rip, J., Kastelein, J.J.P., Kuivenhoven, J.A., Hayden, M.R. (2004) Long-term correction of murine Lipoprotein Lipase Deficiency with AAV1-mediated gene transfer of the naturally-occurring LPLS447X beneficial mutation. Human Gene Therapy, 15 (9) 906–919, 2004. (Cover) PMID: 15353045. (FA) (IF 4.71; Citations 83). Ranked 29 of 169 journals in molecular medicine.
Ross, C.J. and Chang, P.L. Development of small alginate microcapsules for recombinant gene product delivery to the rodent brain. Journal of Biomaterials Science. Polymer Edition, 13 (8) 953–962. 2002. PMID: 12463513. (FA) (IF 3.23; Citations 53). Ranked 66 of 194 journals in bioengineering.
Ross, CJ, Bastedo, L., Maier, S.A., Sands, M.S., and Chang, P.L. 2000. Treatment of a Lysosomal Storage Disease, Mucopolysaccharidosis VII, with Microencapsulated Recombinant Cells. Human Gene Therapy, 11 (15) 2117–2125. PMID: 11044913. (FA) (IF 4.71; Citations 97). Ranked 29 of 169 journals in molecular medicine.
Ross, CJ, Ralph, M., and Chang, P.L. Somatic gene therapy of a neurodegenerative disease using microencapsulated recombinant cells. Experimental Neurology, 166 (2) 276–286. 2000. PMID: 11085893. (FA) (IF 4.71; Citations 71). Ranked 18 of 154 journals in neurology.
Contact Details
Office 6602, Pharmaceutical Sciences Building